BioSpectrum ASIA EDITION
the business of Bio & Health Sciences

Acadia Pharma to commercialise DAYBUEÂ® STIX (trofinetide) in Japan for treatment of Rett syndrome

November 17, 2026 | News

Trofinetide is a synthetic version of a naturally occurring molecule known as the tripeptide glycine-proline-glutamate



Acadia Pharmaceuticals Inc. has entered into an exclusive distribution agreement with KYORIN Pharmaceutical, for the commercialisation of DAYBUE® STIX (trofinetide) powder for oral solution in Japan for the treatment of Rett syndrome.

Under the terms of the agreement, KYORIN will be responsible for leading the commercialisation of DAYBUE STIX in Japan and the related regulatory activities on behalf of Acadia. Acadia will receive an upfront payment of $30 million and is eligible to receive future regulatory and sales milestone payments as well as a share of net sales of DAYBUE STIX in Japan.

Acadia recently completed a Phase 3 study of trofinetide in Japan, with results consistent with the pivotal LAVENDER™ Phase 3 study.

Trofinetide is a synthetic version of a naturally occurring molecule known as the tripeptide glycine-proline-glutamate (GPE). The mechanism by which trofinetide exerts therapeutic effects in patients with Rett syndrome is unknown. Trofinetide was approved for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older by the US Food and Drug Administration in March 2023 under the trade name DAYBUE or DAYBUE STIX.